ArticleBMC cardiovascular disorders2025
Impact of hyperbilirubinemia on rat cardiomyocyte injury.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transforming Toxicity into Therapy: Exploring Bilirubin's Benefits and Its Molecular Role in Cardiac Health and Disease.Biomolecules · 2026Review
- SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate bilirubin-induced injury in rat myocardial cells at varying concentrations.
methodsThe study utilized the rat cardiomyocyte cell line H9C2 and primary rat cardiomyocytes. Bilirubin-rich and control sera were prepared, and cells were cultured for 48 h with or without vitamin C. Cell viability was assessed using the CCK-8 assay, while superoxide dismutase (SOD), glutathione peroxidase (GPx), Na
resultsBilirubin treatment markedly reduced the viability of H9C2 cells and primary rat cardiomyocytes compared to the control group. Additionally, it elevated the levels of cardiac injury markers, including cTn-I and CK-MB in the culture supernatant. Conversely, bilirubin exposure led to a decline in the release of GPx, Na
conclusionsHyperbilirubinemia induces concentration-dependent cardiotoxicity in rat models, while vitamin C supplementation partially mitigates bilirubin-induced myocardial damage.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.